24-25 novembre 2023
CONGRESSO ATBV 2023
Filmati dei lavori
I giornata
WHAT IS THE OPTIMAL STRATEGY FOR LDL-C REDUCTION AFTER AN ACUTE MYOCARDIAL INFARCTION?
Moderatori: Leonardo De Luca, Alberto Margonato
Position #1: PCSK9-I with Monoclonal Antibodies Remains the Standard – Giuseppe Patti
Position #2: The siRNA Approach with Inclisiran Will Take Over – Pierfranco Terrosu
Position #3: Bempedoic acid: More than Just an Alternative to PCSK9-I – Paolo Calabrò
INFLAMMATION: THE NEXT ACTIONABLE TARGET IN PATIENTS WITH CARDIOVASCULAR AND RENAL DISEASE?
Moderatori: Pasquale Perrone Filardi, Claudio Fresco
Colchicine and Beyond: emerging targets in inflammation in patients to acute and chronic coronary syndrome use – Massimo Imazio
Interleukin-1 and Interleukin-6 inhibition – Roberto Pontremoli
State of the Art Lecture: Inflammation and Immunity as Targets in Cardiovascular and Renal Diseases – Raffaele De Caterina
II giornata
ANTITHROMBOTIC STRATEGIES FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASE
Moderatori: Leonardo Bolognese, Luigi Maria Oltrona Visconti
Is Aspirin Over for Primary Prevention? – Bianca Rocca
Chronic Antiplatelet Monotherapy in Coronary Artery Disease: P2Y12-I or Aspirin? – Felice Gragnano
Antithrombotic Management of Peripheral Artery Disease: A Complex Mosaic – Davide Capodanno
State-of-the-Art Lecture: The End of the «DAPT era» – Marco Valgimigli